Search:   Advanced Search   Gallery   About Us   Contact Us   עברית   Supreme Court Deputy-President Eliezer Rivlin (ret.) Joins Hebrew University Faculty of Law Not just our cars, but also living organisms need antifreeze to survive in the cold Nobel laureate Dr. Bruce Beutler to lecture, receive award at Lautenberg Center for Immunology and Cancer Research Learn in Israel, Heal the World: Public health leaders from 20 countries will spend nine days learning and exchanging ideas in Jerusalem Music on our Minds: international conference on music and the brain will mix science and concerts German foundation awards two €250,000 prizes to Hebrew University researchers in Humanities and Social Sciences Professor Yoram Bilu to receive Israel Prize in sociological and anthropological research How to cut down on crime? Focus police in concentrated ‘hot spots,’ says Hebrew University criminologist Healing the world: 70 graduates of International Master’s in Public Health program to attend 2nd alumni workshop, reunion in Jerusalem It's a bird, it's a plane, it's…. Hebrew U?   13 September, 2012 Jerusalem Mayor Nir Barkat visits biomed lab of Hebrew University’s Prof. Yechezkel Barenholz Barenholz leads a team of mostly Hebrew University scientists who are developing advanced nano-medicines in Jerusalem Jerusalem Mayor Nir Barkat pays a visit to Hebrew University’s Prof. Barenholz at his biomedical company LipoCure (Photo: Flash 90) Jerusalem Mayor Nir Barkat paid a visit this week to LipoCure, a pharmaceutical company founded by Prof. Yechezkel (Chezy) Barenholz of the Hebrew University’s Faculty of Medicine. Prof. Barenholz leads a team of nearly twenty scientists, mostly from the Hebrew University, who are developing advanced nano-drugs for treating cancer and inflammatory diseases, and for use as local anesthetics. He previously developed Doxil, an anticancer drug which is the first nano-medicine and also the first liposomal drug approved by the United States’ Food and Drug Administration and worldwide. Prof. Barenholz stressed the importance of developing a biomedical industry in Jerusalem, and expressed the hope that the Jerusalem Municipality will increase its aid to local companies operating in the sector. Barenholz told Mayor Barkat that because of the importance he attaches to Jerusalem, he insisted on establishing LipoCure in the nation’s capital, even though it would cost less to operate the company in a different city. He also said that LipoCure is not satisfied merely to conduct research and development, and added that within a year the company will establish a production plant in Jerusalem, which could generate revenues of hundreds of millions of dollars every year. The Mayor briefed Prof. Barenholz on the ways in which the municipality promotes the city’s biomedical industry and promised to offer as much support as possible to LipoCure and similar companies. Displaying great interest in the drug development process, Barkat said he hopes LipoCure’s success will pave the way for other biomedical companies in the city. Mayor Barkat, whose father was a professor of physics at the Hebrew University. obtained his bachelor's degree in computer science at the Hebrew University.
Design by ICS © All rights reserved to The Hebrew University of Jerusalem